PIK3CA and T-cell non-Hodgkin lymphoma: To explore potential drugs that are effective against PI3K inhibitor (copanlisib and duvelisib)-resistant B- and T-cell lymphomas, we used high-throughput screening assays, which led to the identification of the JAK inhibitor, BSK805.